Scilex (SCLX) to Post Quarterly Earnings on Wednesday

Posted by George Bondi on Sep 1st, 2026

Scilex (NASDAQ:SCLX – Get Free Report) is projected to post its Q2 2026 results before the market opens on Wednesday, September 2nd. Analysts expect Scilex to post earnings of ($0.1813) per share and revenue of $16.00 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 7:00 AM ET.

Scilex (NASDAQ:SCLX – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($16.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($16.47). The company had revenue of $7.64 million during the quarter, compared to analyst estimates of $16.00 million.

Scilex Price Performance

SCLX opened at $5.49 on Tuesday. The stock’s 50 day moving average price is $7.17 and its 200 day moving average price is $7.38. The stock has a market cap of $46.61 million, a P/E ratio of -0.11 and a beta of 1.67. Scilex has a 12 month low of $4.20 and a 12 month high of $34.27.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SCLX. Weiss Ratings reissued a “sell (e+)” rating on shares of Scilex in a research note on Tuesday, June 16th. Wall Street Zen cut shares of Scilex from a “sell” rating to a “strong sell” rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Check Out Our Latest Analysis on SCLX

Hedge Funds Weigh In On Scilex

Several hedge funds have recently made changes to their positions in SCLX. BNP Paribas Financial Markets lifted its stake in Scilex by 189.6% during the third quarter. BNP Paribas Financial Markets now owns 7,430 shares of the company’s stock valued at $146,000 after purchasing an additional 4,864 shares during the last quarter. Bank of America Corp DE grew its position in Scilex by 81.0% in the third quarter. Bank of America Corp DE now owns 17,387 shares of the company’s stock worth $342,000 after buying an additional 7,783 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new position in shares of Scilex in the fourth quarter valued at $150,000. Norges Bank bought a new position in shares of Scilex in the second quarter valued at $80,000. Finally, Renaissance Technologies LLC lifted its position in shares of Scilex by 100.7% during the 4th quarter. Renaissance Technologies LLC now owns 38,464 shares of the company’s stock valued at $469,000 after acquiring an additional 19,300 shares during the last quarter. Institutional investors and hedge funds own 69.67% of the company’s stock.

Scilex Company Profile

(Get Free Report)

Scilex Holdings, Inc (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways.